James Dougherty, M.D., Arcus Ventures Fund
Jim Dougherty is a co-founder and general partner of Arcus Ventures Fund (AVF), an oncology-focused venture capital fund based in New York City. AVF was founded in 2007 and invests in therapeutics, devices, diagnostics and services related to cancer. Dr. Dougherty is a medical oncologist trained at Memorial Sloan Kettering Cancer Center, where he was also a faculty member including the administrative role of Deputy Physician in Chief for 5 years, overseeing clinical operations for the center.
Dr. Dougherty is a graduate of Georgetown University, Hershey Medical School of Penn State University and received an M.B.A. from the Wharton School of the University of Pennsylvania.
Peter K. Shagory, Baird Venture Partners
Pete Shagory joined Baird Venture Partners in 2004 and concentrates on healthcare and life science investments, focusing in medical devices, life science tools, diagnostics, and healthcare services.
Prior to joining Baird Venture Partners, he spent five years at Vector Fund Management, a life-sciences venture capital firm, investing broadly across the medical device and biotechnology fields. Prior to Vector, he spent over six years in corporate finance, mergers & acquisitions and merchant banking at JP Morgan & Co. and Banc One Capital Corporation.
Pete is currently a Director of Celleration, CoAxia, Core Essence Orthpaedics and Molecular Imaging. He is a former Board Chairman and Director of Accuri Cytometers and a former Director of Arbor Surgical Technologies, PharMEDium Healthcare Corporation and NimbleGen Systems. Pete is the founding Chair of AdvaMed’s National Venture Capital Advisory Board and also serves on the Boards of the Mid-America Healthcare Investors Network (MHIN) and the Children's Memorial Hospital Foundation. He received his undergraduate degree in Business Administration and Finance from Miami University in Oxford, Ohio, and his M.B.A. from the Amos Tuck School at Dartmouth College.
Stephen J. Sullivan, CRO Advisors LLC
Steve Sullivan founded CRO Advisors LLC in 2010 as a specialty consulting firm to advise CROs, their partners and their investors as the CRO industry goes through unprecedented change.
In February 2006 Steve joined Harlan Laboratories, Inc.as CEO following Genstar Capital’s 2005 acquisition of controlling interest in the Company and served as CEO until January 2010. Prior to Harlan, he was a Senior Vice President with Covance, Inc. where he managed Clinical operations for three years and the Central Laboratory Group for four years.
Prior to Covance, Steve was Chairman and CEO of Xenometrix, Inc., a drug discovery tool company. Previously, he served in several senior management positions at Abbott Laboratories, including Vice President of Worldwide Marketing for Abbott Diagnostics, and Vice President and General Manager of the Diagnostic Assay Sector and also held senior management positions at Lyphomed, Inc., Dart and Kraft Inc., and Baxter International.
Concurrent with business assignments, Steve was a Senior Lecturer at the Kellogg Graduate School of Management at Northwestern University from 1982 to 1997. He has served on several public, private and not-for-profit boards and is currently a Director for PDI, Inc. (NASDAQ: PDII), a contract sales and marketing company, and non-executive Chairman of the Board of Molecular Imaging. Steve was an infantry company commander in the U. S. Marine Corps and received his M.B.A. from Rutgers University and B.S. from the University of Dayton.
Mark Eisenach, Ridgeview Partners LLC
Mark Eisenach has more than 20 years of corporate development, strategy, and executive management experience, primarily in the life sciences and high technology industries.
He is currently founder and Managing Director of Ridgeview Partners LLC, a Princeton, N.J.-based corporate advisory firm, and previously served as CEO of pharmaceutical services company Acurian Inc. Prior to that, he held a variety of senior executive positions at Covance Inc., one of the world’s largest and most comprehensive drug development services companies. In these roles, he led Covance's worldwide business strategy, mergers and acquisitions, business partnerships and global marketing efforts, serving on the company's Global Leadership Council.
Earlier in his career, Mr. Eisenach spent eight years at the Boston Consulting Group and was a tax economist at Price Waterhouse. He received his A.B. from Harvard College and his M.B.A. from Harvard Business School. He also holds Series 82 and Series 63 security licenses with Walter Greenblatt & Associates, Ridgeview Partners' investment banking partner.